Search research articles
Contact Us
Filters
Showing results (101-110 of 110) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 110 results.
Gastroenterology
|
June 21, 2024
Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension
Chang-Peng Zhu, Shu-Qing Liu, Ke-Qi Wang, et al.
Chinese Medical Journal
|
April 12, 2012
Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population
Xiao-ping Zhang, Zhi-bin Bai, Bao-an Chen, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
September 2, 2008
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]
Mei Dong, Feng-Yi Feng, Yang Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study
Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, et al.
Archives of Medical Science : AMS
|
October 3, 2014
A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
Ke-Jun Liu, Zhong-Zhen Guan, Ying Liang, et al.
The Lancet. Oncology
|
March 22, 2015
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Xi-Chun Hu, Jian Zhang, Bing-He Xu, et al.
Therapeutic Advances in Medical Oncology
|
November 5, 2020
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study
Qing Yuan Zhang, Tao Sun, Yong Mei Yin, et al.
Chinese Medical Journal
|
July 31, 2018
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study
Jian-Qiu Wu, Yong-Ping Song, Li-Ping Su, et al.
Translational Lung Cancer Research
|
July 28, 2018
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel
Yi-Long Wu, Chang-Li Wang, Mei-Lin Liao, et al.
ESMO Open
|
August 30, 2017
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel
Yi-Long Wu, Chang-Li Wang, Yan Sun, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 110) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 110 results.
Gastroenterology
|
June 21, 2024
Targeting 5-Hydroxytryptamine Receptor 1A in the Portal Vein to Decrease Portal Hypertension
Chang-Peng Zhu, Shu-Qing Liu, Ke-Qi Wang, et al.
Chinese Medical Journal
|
April 12, 2012
Polymorphisms of dihydropyrimidine dehydrogenase gene and clinical outcomes of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population
Xiao-ping Zhang, Zhi-bin Bai, Bao-an Chen, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
September 2, 2008
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]
Mei Dong, Feng-Yi Feng, Yang Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2014
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study
Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, et al.
Archives of Medical Science : AMS
|
October 3, 2014
A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers
Ke-Jun Liu, Zhong-Zhen Guan, Ying Liang, et al.
The Lancet. Oncology
|
March 22, 2015
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial
Xi-Chun Hu, Jian Zhang, Bing-He Xu, et al.
Therapeutic Advances in Medical Oncology
|
November 5, 2020
MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study
Qing Yuan Zhang, Tao Sun, Yong Mei Yin, et al.
Chinese Medical Journal
|
July 31, 2018
Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study
Jian-Qiu Wu, Yong-Ping Song, Li-Ping Su, et al.
Translational Lung Cancer Research
|
July 28, 2018
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel
Yi-Long Wu, Chang-Li Wang, Mei-Lin Liao, et al.
ESMO Open
|
August 30, 2017
A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel
Yi-Long Wu, Chang-Li Wang, Yan Sun, et al.
Page
of 11